Q4 2024 Earnings Call Transcript March 11, 2025 Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Analysts have set 12-month price targets for Voyager Therapeutics, revealing an average target of $18.93, a high estimate of ...

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a ...

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Voyager Therapeutics (VYGR) to $10 from $12 and keeps an Overweight rating on ...

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $1.25 per share a year ago. These ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP ...

VOYAGER THERAPEUTICS ($VYGR) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting revenue ...

The gene therapy company posted revenue of $6.3 million in the period, which also missed Street forecasts. Five analysts surveyed by Zacks expected $20.1 million. For the year, the company reported a ...

LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company ...

HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a report released on ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...